2 AIM: In this study, we investigated the role and mechanism of Salt-induced kinase 3 1 (SIK1) in regulation of hepatic glucose and lipid metabolism in a high-fat food 4 (HFD) and streptozocin (STZ)-induced type 2 diabetes mellitus (T2DM) rat model. 5 Methods: A diabetic rat model treated with HFD plus low-dose STZ was 6 developed and was transduced to induce a high expression of SIK1 in vivo via a 7 tail-vein injection of a recombinant adenoviral vector. The effects on hepatic 8 glucogenetic and lipogenic gene expression, systemic metabolism and pathological 9 changes were then determined.
Introduction

28
T2DM is characterized by hyperglycemia and insulin resistance (IR) and is the 6 / 28 89 phosphorylation-deficient Srebp1-c mutant [17] . A previous report has shown that 90 lipogenic genes, such as FAS and ACC, are up-regulated by SIK1 knockdown in 91 mouse liver, whereas overexpression of SIK1 reduces expression levels of SREBP-1c 92 target genes, suggesting that SIK1 could regulate lipogenic gene transcript [17] . 93 SIK1-induced phosphorylation of SREBP-1c at Ser329 is thought to be critical for the 94 suppression of SREBP-1c transcription activity [17] . Our previous study 95 demonstrated that overexpression of SIK1 suppressed the expression of SREBP-1c 96 and its target genes in HepG2 cells cultured in a high glucose environment [18] . Thus, 97 modulation of SREBP-1c activity by SIK1 would provide an attractive means for the 98 regulation of hepatic lipogenesis. In the diabetic conditions, normal regulation of 99 gluconeogenesis and lipogenesis is disrupted; hence the SIK1/CRTC2 and 100 SIK1/SREBP-1c pathways may serve as therapeutic targets to modulate metabolic 101 disorders in diabetic patients with NAFLD. 102 To date, the role and mechanism of SIK1 in the liver of the HFD/STZ-induced 103 T2DM rat model remains completely unknown. Because the diabetic rat model treated 104 with HFD plus low-dose STZ replicates the natural history and metabolic 105 characteristics of human T2DM and develops most of the biochemical and 106 pathological symptoms [19] [20] [21] [22] [23] [24] associated with T2DM in humans, the diabetic rat 107 model is particularly suitable for pharmaceutical research [25] . Thus, it is of interest 108 to define the effect of SIK1 on hepatic gluconeogenesis and lipogenesis of the control rats were injected with the same volume of citrate buffer. Diabetes was 142 defined by fasting serum glucose >11.1 mmol/L 72 h after STZ injection. The diabetic 143 rats were randomly divided into three groups: diabetes mellitus (DM) group (n=6), 144 Ad-Sik1 group (n=8), and Ad-GFP group (n=6). The Ad-Sik1 and Ad-GFP groups 145 received an injection of Ad-Sik1 or Ad-GFP at an optimized dose of 5×10 9 PFU via 146 tail vein once a week for 8 weeks. The DM and normal control groups were given an 147 equal volume of normal saline. The liver tissues were fixed with 4% paraformaldehyde for paraffin embedding.
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The paraffin-embedded sections were subjected to immunohistochemical staining for 186 SIK1, CRTC2, PEPCK, G6pase, SREBP-1c, FAS and ACC in the liver. The tissue 187 sections were incubated with rabbit anti primary antibody (1:100). After washing with 188 PBST, the sections were incubated with secondary antibody, and the 189 diaminobenzidine method was used. Next, the SIK1, CRTC2, PEPCK, G6pase, study are listed in S1 Table. 208 Western blot 209 SIK1, SIK1 (S577), SIK1 (T182), CRTC2, CRTC2 (S171), PEPCK, G6pase, Neither the Ad-SIK1 group nor the Ad-GFP group showed significant differences in 244 blood glucose or body weight. As shown in Table 1, To determine whether SIK1 overexpression ameliorates hyperglycaemia by 295 decreasing endogenous glucose production in the liver, we measured the mRNA and 296 protein of SIK1, CRTC2, PEPCK and G6pase in the liver. RT-PCR analysis showed 297 that SIK1 was significantly elevated in the Ad-SIK1 group compared to the DM group, 298 while CRTC2, PEPCK and G6pase were significantly reduced, indicating an 299 inhibitory effect of SIK1 in liver glucogenesis ( Fig 3B) . Indeed, the Western blot 300 results showed that SIK1 was significantly decreased in the DM group compared to 301 the control group, whereas CRTC2, PEPCK and G6pase were significantly elevated in 302 the DM group. SIK1 overexpression significantly increased the protein level of SIK1, 303 but decreased the protein levels of CRTC2, PEPCK and G6pase in liver compared 304 with the DM group ( Fig 3A) . Meanwhile, the phosphorylation level of SIK1 at Ser577 305 was drastically reduced, whereas the level of pT182 SIK1 and pS171 CRTC2 was Since the discovery of the SIK family, the roles of SIK isoforms (SIK1/2/3) in 333 glucose and lipid metabolism have been extensively investigated [6-9, 12, 14, 17, 18] . 334 However, the biological function of SIK1 remains poorly understood in 335 HFD/STZ-induced T2DM rats. In this study, we found that the expression of hepatic 
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This study established a model of T2DM rats treated with HFD plus low-dose 345 STZ. The HFD/STZ-induced diabetic rats exhibited classic diabetic symptoms of 346 polyuria, polydipsia and weight loss. The T2DM rats also showed high blood glucose, 347 high TG and TC than normal control rats, which was consistent with previous report for the first time demonstrated that SIK1 mRNA and protein expression were 361 significantly reduced in the livers of HFD/STZ-induced diabetic rats, which was 362 consistent with our previous in vitro studies [8, 18] , suggesting that the expression of 363 SIK1 is inhibited in diabetic states.
364
Phosphorylation at Thr182 by LKB1 is essential for switching on the SIK1 365 kinase activity [7, 28] . The Thr182 of SIK1 is phosphorylated by LKB1, resulting in 366 conversion from inactive SIK1 to the active form [6] . Consistent with previous in 367 vitro observations [8, 18] , this in vivo study indicated that the level of Thr-182 368 phosphorylation, as well as the expression of SIK1 mRNA and protein, was 369 downregulated in the livers of HFD/STZ-induced diabetic rats, suggesting that the 370 SIK1 kinase activity may be suppressed in diabetic states. As expected, Ad-SIK1 371 treatment significantly elevated the level of pT182 SIK1 compared to the DM group.
372
In addition, the intracellular distribution of SIK1 is closely associated with its 373 functional activity. Ser-577 is a determinant of the intracellular distribution of SIK1.
374
Moreover, inactive SIK1 as well as CREB-repressing active SIK1 are present as 19 / 28 375 Ser577-dephosphorylated forms and are localized in the nucleus [3, 6, 8] . 376 Phosphorylation of SIK1 at Ser577, which causes the nucleus export of SIK1, leads to expression. This effect was consistent with previous reports [12, 17] .
424
In summary, the present study demonstrates that SIK1 mRNA and protein expression 425 are significantly reduced in the livers of HFD/STZ-induced diabetic rats.
426
Overexpression of SIK1 ameliorates hyperglycaemia and fatty liver by suppressing 427 hepatic gluconeogenesis and lipogenesis in HFD/STZ-induced T2DM rats. This 428 protective effect of SIK1 may be derived from its interference with the SIK1/CRTC2 429 and SIK1/SREBP-1c pathways. Up-regulating hepatic SIK1 expression may represent 430 an attractive means for the treatment of T2DM and NAFLD. Figure 6 illustrates the 431 possible mechanisms of SIK1 in attenuating T2DM with NAFLD. 
